- used as a bronchodilator in infants with reversible airway obstruction
- a selective beta 2 adrenergic agent; the main effect following inhalation or oral administration is broncholidation
- has some effects on peripheral vasculature and may produce a small decrease in diasolitic blood pressure
- its action is believed to result from an increased level of intracellular cyclic AMP
- most effective when administered via inhalation, but may also be given orally; it has beam estimated that less than 10% of an orally administered dose reaches the bronchial tree
- the most common adverse effects are dose related: tachycardia, arrhythmias, tremor, hypokalemia, peripheral vasodilation
- irritable behaviour, GI upset
- use with caution, if at all, in infants with hypertension
- 0.05 to 0.5 mg/kg, via inhalation, every 2 to 6 hours, prn (equivalent to: 0.01 to 0.1 mL/kg of 5mg/mL respirator solution
- 5 mg/mL respirator solution
- McEvoy G K (ed): AHFS Drug Information, American Society of Hospital Pharmacists, 1991.
- Gomella TL (Ed): Neonatology - Management, Procedures, On-Call Problems, Diseases, Drugs, 1992, Appleton and Lange, Norwalk, Connecticut.
- Bhatt DR, Furman GI, Reber DJ et al: Neonatal Drug Formulary, 1990-1991, 2nd Edition, Fontana, California 92334.
- Taketomo CK, Hodding JH and Kraus DM: Pediatric Dosage Handbook, Lexi-Comp Inc., Cleveland, 1992.
- Yaffe SJ and Aranda JV (Eds): Pediatric Pharmacology-Therapeutic Principles in Practice, WB Saunders Co, Toronto, Ontario 2nd Edition, 1992.
- Young TE and Mangum OB: Neofax - A Manual of Drugs Used in Neonatal Care, Columbus, Ohio: Ross Laboratories, 1992.